Nicolas Thonnart
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
CD39 is expressed by a wide range of cutaneous T-cell lymphomas.
Journal: Skin health and disease
Published: April 05, 2024
Large-cell transformation is an independent poor prognostic factor in Sézary syndrome: analysis of 117 cases.
Journal: The British journal of dermatology
Published: April 25, 2022
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
Journal: Cancer immunology, immunotherapy : CII
Published: December 24, 2021
Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome.
Journal: Blood
Published: November 10, 2021
PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4+ T Lymphocytes.
Journal: The Journal of investigative dermatology
Published: September 07, 2020
Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients.
Journal: The Journal of investigative dermatology
Published: August 01, 2018
Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 19, 2016
KIR3DL2 is a coinhibitory receptor on Sézary syndrome malignant T cells that promotes resistance to activation-induced cell death.
Journal: Blood
Published: November 22, 2014
IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
Journal: Cancer research
Published: November 02, 2014
KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.
Journal: The Journal of investigative dermatology
Published: November 07, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026